Lipids Board Review. Ira Goldberg, MD New York University School of Medicine. Which of the following is the best initial therapy choice?

Size: px
Start display at page:

Download "Lipids Board Review. Ira Goldberg, MD New York University School of Medicine. Which of the following is the best initial therapy choice?"

Transcription

1 Lipids Board Review Ira Goldberg, MD New York University School of Medicine 1. A 22 year old male college student is referred for severe hypertriglyceridemia ( 1500 mg/dl [ 17.0 mmol/l]). He has a history of pancreatitis. Height is 67 in (170.2 cm), and weight is 185 lb (84.1 kg) (BMI = 29 kg/m 2 ). He reports that much of this weight gain has occurred in the past 3 years, as he weighed 145 lb (65.9 kg) when he graduated from high school. Question 1 (1/1) Which of the following is the most important immediate lifestyle change to recommend? A. Avoid omega 3 saturated fats B. Reduce intake of noncomplex carbohydrates C. Avoid alcohol D. Drink more fruit juice E. Reduce intake of fried foods 1% 1 6 1% 1 2. A 41 year old woman with a 2 year history of infertility is noted to have a triglyceride concentration of 450 mg/dl (5.08 mmol/l). Her physicians are concerned that her induction cycle will lead to more marked hypertriglyceridemia and risk for pancreatitis. Her height is 65 in (165.1 cm), and weight is 168 lb (76.4 kg) (BMI = 28 kg/m 2 ). Question 1 Question 2 (1/1) Which of the following is the best initial therapy choice? A. Lifestyle changes B. Cholestyramine C. Fibric acid D. A statin E. Fish oil Question 2 66% 11% 18% 3. A 20 year old woman from Montreal is referred to you when an episode of pancreatitis occurs after she had been prescribed oral contraceptive pills by the college infirmary. On physical examination, you note that she has eruptive xanthomas and lipemia retinalis. She relates that as a child and teen she sometimes had abdominal pain after eating fatty foods, which she learned to avoid. Question 3 (1/3) 1

2 Lipemia Retinalis Question 3 (2/3) Question 3 (3/3) Which of the following is the genetic etiology most likely to have caused her hypertriglyceridemia? A. Apolipoprotein CII deficiency B. Adipose triglyceride lipase deficiency C. Apolipoprotein A5 deficiency D. Lipoprotein lipase deficiency E. Hepatic lipase deficiency 78% TG and Lipases: Lipoprotein lipase (LpL) and Hepatic lipase (HL) Hydrocarbon tail LpL O C O Glycerol O O C O O C Hydrocarbon tail Hydrocarbon tail Question 3 Lipolysis Regulation TG-triglyceride, CE-cholesteryl ester ENDOTHELIAL CELL 4. A 30 year old woman without diabetes mellitus has acute pancreatitis and a triglyceride level greater than 5000 mg/dl ( mmol/l). She is admitted to the hospital and is treated with supportive care as is recommended for all cases of pancreatitis. Question 4 (1/1) 2

3 Which of the following is an additional therapy that could be used as a method to reduce liver production of triglycerides in this patient? A. Insulin and glucose B. Atorvastatin C. Heparin D. Androgen E. Metformin Question 4 86% 6% 5. You are referred a 48 year old man with a 12 year history of coronary artery disease and multiple hospitalizations for coronary artery stent placements. The patient s family has a strong history of heart disease: his father and 2 paternal uncles died before age 50 years. The patient takes atorvastatin, 80 mg daily. Total cholesterol = 210 mg/dl (5.44 mmol/l) LDL cholesterol = 150 mg/dl (3.89 mmol/l) HDL cholesterol = 40 mg/dl (1.04 mmol/l) Triglycerides = 100 mg/dl (1.13 mmol/l) Question 5 (1/1) On physical examination, you should look for which of the following findings? A. Lipemia retinalis B. Achilles xanthomas C. Eruptive xanthomas D. Palmar xanthomas E. Arthropathy 57% 1 1 Question 5 6. You are referred a 42 year old man with a family history of familial hypercholesterolemia and a recent myocardial infarction. While on rosuvastatin, 40 mg daily, and adhering to a low fat, low cholesterol diet, his LDL cholesterol concentration is 150 mg/dl (3.89 mmol/l). Because recent clinical trials reported no benefit of niacin and ezetimibe in statin treated patients, his primary care physician discontinued these 2 medications. While taking niacin and ezetimibe, his LDL cholesterol concentration was below 100 mg/dl ( 2.59 mmol/l). You elect to restart niacin and ezetimibe. You explain that the aforementioned trial results do not apply to him because of which of the following? A. His diet is optimal B. He will take a different formulation of niacin than was used in the trials C. His baseline LDL cholesterol level is different from the average baseline level in the trials D. Coronary intervention has changed since the positive trials with niacin took place E. His microbiome differs from that of 30 years ago 9 Question 6 (1/1) Question 6 3

4 LOW CHOLESTEROL Progression Regression HIGH 7. You are referred a 58 year old woman who has the physical finding shown in the photograph. She has been in good health and has no personal or family history of vascular disease. Moreover, she is unaware of having a dyslipidemia and is sure that her cholesterol was checked when she was younger. After menopause, she gained 20 lb (9.1 kg), and during the past year she has attempted to reduce her weight with a high fat, lowcarbohydrate diet. On this diet, her BMI has decreased from 35 to 27 kg/m 2. Her total cholesterol concentration has increased to greater than 600 mg/dl ( mmol/l) with an equal increase in triglycerides. Thyroid function is normal. Question 7 (1/2) To make the definitive diagnosis of this patient s disorder, you should order which of the following tests? A. Apolipoprotein AI radioimmunoassay B. Apolipoprotein E radioimmunoassay C. Assessment of LDL particle size D. Apolipoprotein E genotyping E. Lipoprotein(a) gene analysis 8% % 2 Question 7 (2/2) Question 7 Apolipoproteins Liver ApoB100 MTTP VLDL Lipids Intestine Dietary Lipids ApoB48 MTTP Protein components of lipoprotein Functions include: serving as membrane stabilizers and cofactors for enzyme activation; interacting with receptors to promote lipid metabolism Four major classes: A, B, C, and E IDL VLDL TG/CE VLDL TG/CE Lipoprotein lipase LDL Receptor Chylomicrons TG/RE/CE Chylomicron Remnants RE/CE LDL Liver Heart 4

5 8. A 48 year old woman with cardiovascular disease and a 10 year history of type 2 diabetes mellitus is referred by her internist for more intensive lipid lowering therapy. While on her current regimen of atorvastatin, 80 mg daily, she has recently required a stent for a new right coronary artery occlusion. On metformin and once daily, long acting insulin, her hemoglobin A 1c level is less than 7% ( 0.070). During the past 3 years, the patient has gained 30 lb (13.6 kg). Question 8 (1/2) Total cholesterol = 160 mg/dl (4.14 mmol/l) Triglycerides = 300 mg/dl (3.39 mmol/l) HDL cholesterol = 35 mg/dl (0.91 mmol/l) LDL cholesterol = 65 mg/dl (1.68 mmol/l) Non HDL cholesterol = 125 mg/dl (3.24 mmol/l) In addition to encouraging exercise and weight loss, you recommend fenofibrate as an approach to reduce her non HDL cholesterol. Question 8 (2/2) Which of the following might be the additional benefit of fenofibrate treatment in this patient with type 2 diabetes? A. Decreased hemoglobin A 1c level B. Decreased proteinuria C. Decreased retinopathy D. Decreased blood pressure E. Increased insulin sensitivity 1 46% 3 Comparison of ACCORD Subgroup Results With Those From Previous Fibrate Studies Trial (Drug) Primary Endpoint: Entire Cohort (P value) HHS (Gemfibrozil) -3 (.02) Lipid Subgroup Criterion Primary Endpoint: Subgroup TG >200 mg/dl LDL-C/HDL-C >5.0-71% (0.005) BIP (Bezafibrate) -7. (.24) TG >200 mg/dl -39. (0.02) FIELD (Fenofibrate) -11% (.16) TG >204 mg/dl HDL-C <42 mg/dl -27% (0.005) ACCORD (Fenofibrate) -8% (.32) TG >204 mg/dl HDL-C <34 mg/dl -31% Question 8 9. A 50 year old man with type 2 diabetes mellitus has a hemoglobin A 1c level of 7.8% (0.078) and is currently treated with rosuvastatin, 40 mg daily. His other risk factor for cardiovascular disease is hypertension. Total cholesterol = 185 mg/dl (4.79 mmol/l) LDL cholesterol = 120 mg/dl (3.11 mmol/l) HDL cholesterol = 45 mg/dl (1.17 mmol/l) Triglycerides = 100 mg/dl (1.13 mmol/l) Question 9 (1/1) Which of the following added cholesterolreducing therapies also might assist with his glucose control? A. Niaspan B. Colesevelam C. Pitavastatin D. Ezetimibe E. Anacetrapib Question 9 8 5

6 10. A 52 year old woman with familial hypercholesterolemia has been treated with rosuvastatin, 40 mg daily, and ezetimibe, 10 mg daily, for the past 5 years. This combination has reduced her total cholesterol concentration from 385 to 215 mg/dl (9.97 to 5.57 mmol/l) and her LDL cholesterol concentration from 300 to 120 mg/dl (7.77 to 3.11 mmol/l). She now presents with a total cholesterol concentration of 260 mg/dl (6.73 mmol/l) and reports muscle pains. Creatine phosphokinase and blood glucose levels are not elevated. Question 10 (1/1) Which of the following tests would be most useful? A. Dexamethasone suppression B. FSH measurement C. TSH measurement D. Urinary protein measurement E. Prolactin measurement Question 10 88% 7% 11. A 45 year old woman with rheumatoid arthritis is referred for hypercholesterolemia and statin induced myalgia; creatine kinase has never been documented to be elevated. Her physician has tried treating her with simvastatin, atorvastatin, and rosuvastatin. Which of the following is the best next step in this patient s care? A. Treat with a statin plus coenzyme Q10 B. Treat with rosuvastatin once weekly C. Measure lipoprotein(a) D. Treat with fish oil E. Assess for statin antibodies 37% 48% Question 11 (1/1) Question A 31 year old man with type 2 diabetes mellitus treated with metformin, pioglitazone, atorvastatin, and fenofibrate is referred for the following lipid panel: HDL cholesterol = 5 mg/dl (0.13 mmol/l) LDL cholesterol = 120 mg/dl (3.11 mmol/l) Triglycerides = 300 mg/dl (3.39 mmol/l) On a previous lipid profile 5 years ago, his HDLcholesterol level was 25 mg/dl (0.65 mmol/l). His BMI is 37 kg/m 2, and his hemoglobin A 1c level is 6.3 (0.063). Question 12 (1/1) This marked reduction in HDL cholesterol is most likely due to which of the following? A. Acquired lecithin cholesterol acyltransferase deficiency B. Fenofibrate therapy C. Statin induced hypoalphalipoproteinemia D. Metformin inhibition of ABCA1 E. Erroneous apolipoprotein B precipitation Question % 6% 1 6

7 Causes of Low HDL Cholesterol Hypertriglyceridemia Obesity Insulin resistance Anabolic steroids Rare genetic disorders: LCAT deficiency, apo A I deficiency, ABCA I deficiency, vanishing HDL syndrome due to inflammation 13. A 30 year old woman with a 20 year history of type 1 diabetes mellitus currently treated with an insulin pump is referred to you for advice regarding hypercholesterolemia. Her BMI is 22 kg/m 2. She exercises regularly and maintains a low saturated fat, low cholesterol diet. Aside from insulin, her only other medication is an oral contraceptive. Hemoglobin A 1c = 6.1% (0.061) Total cholesterol = 280 mg/dl (7.25 mmol/l) HDL cholesterol = 110 mg/dl (2.85 mmol/l) LDL cholesterol = 155 mg/dl (4.01 mmol/l) Triglycerides = 75 mg/dl (0.85 mmol/l) Question 13 (1/1) Which of the following should you recommend? A. Continue to rely on lifestyle interventions B. Add fish oil C. Discontinue the oral contraceptive therapy D. Add atorvastatin E. Add colesevelam Question % 36% Osler 1892 Osler s Observations on Diabetes Page 295. It is a disease of adult life. It is a disease of higher classes. The subjects have been excessively fat. More common in cities than in country districts. Hebrews seem especially prone to it. Page 297. The heart shows no characteristic changes The Principles and Practice of Medicine, A 27 year old man is referred to you because of low blood cholesterol levels. Total cholesterol = 56 mg/dl (1.45 mmol/l) HDL cholesterol = 24 mg/dl (0.62 mmol/l) LDL cholesterol = 24 mg/dl (0.62 mmol/l) Triglycerides = 38 mg/dl (0.43 mmol/l) BMI is 24 kg/m 2. He has no obvious medical conditions. You provide him with advice on lifestyle. Which of the following do you advise him is one possible complication from his condition? A. Coronary artery disease B. Nonalcoholic fatty liver disease C. Renal failure D. Tonsillitis E. Myositis 1 51% 1 1 Question 14 (1/1) Question 14 7

8 15. You are referred a 30 year old woman with systemic lupus erythematosus and the following lipid profile: Total cholesterol = 300 mg/dl (7.77 mmol/l) HDL cholesterol = 30 mg/dl (0.78 mmol/l) Triglycerides = 1000 mg/dl (11.30 mmol/l) LDL cholesterol cannot be estimated. Her current medications include prednisone, 20 mg daily; hydrochlorothiazide; lisinopril and metoprolol for hypertension; and infliximab. Question 15 (1/1) You are concerned that medications could be contributing to her dyslipidemia. You recommend which of the following adjustments? A. Switch prednisone to dexamethasone B. Switch metoprolol to amlodipine C. Switch infliximab to gold therapy D. Switch hydrochlorothiazide to chlorthalidone E. Discontinue lisinopril Question 15 48% 17% 26% 16. You are consulted about 60 year old man in the medical intensive care unit who has been on a respirator for 3 weeks and is recovering from a communityacquired pneumonia. The patient is cachectic. He is not hypotensive. His electrolytes are normal, and his albumin level is 2.0 g/dl (20 g/l). His glucose concentration is 147 mg/dl (8.16 mmol/l) and he is being treated with insulin. His total cholesterol level is 90 mg/dl (2.33 mmol/l), and the attending physicians are concerned that this could lead to adrenal insufficiency. A cosyntropin stimulation test reveals a baseline cortisol concentration of 4 g/dl (110.4 nmol/l) and stimulation to 17 g/dl (469.0 nmol/l). Question 16 (1/1) Which of the following is the most likely reason for this test result? A. Abetalipoproteinemia B. Acquired hypocholesterolemic cortisol deficiency C. Normal stimulation, but baseline adrenal insufficiency D. Cortisol binding globulin deficiency E. Hypothalamic/pituitary insufficiency Question 16 6% 7% 77% 17. You see a 55 year old man who is anxious about his cardiovascular risk. He exercises regularly; has a blood pressure of 115/65 mm Hg; and avoids high fat, high cholesterol foods. His father was a World War II veteran who smoked 2 packs of cigarettes daily until having a myocardial infarction at age 62 years. Total cholesterol = 190 mg/dl (4.92 mmol/l) LDL cholesterol = 105 mg/dl (2.72 mmol/l) HDL cholesterol = 70 mg/dl (1.81 mmol/l) Triglycerides = 75 mg/dl (0.85 mmol/l) Question 17 (1/1) Which additional test could you order to best assess this man s cardiovascular disease risk? A. Coronary calcium score B. LDL particle size distribution C. Apolipoprotein B by immunoassay D. Antioxidant levels E. Serum palmitate measurement Question % 8

9 18. A gastroenterologist refers to you a 28 year old woman with primary biliary cirrhosis. During her workup, the gastroenterologist noted that her total cholesterol level was 450 mg/dl (11.66 mmol/l). In this situation, her cholesterol elevation is associated with an increase in which lipidcontaining particle? A. Lipoprotein X B. Lipoprotein(a) C. Small, dense LDL D. Retinal binding protein 4 E. HDL % Question 18 (1/1) Question You are asked to see a 35 year old Japanese American woman with the following lipid panel: Total cholesterol = 245 mg/dl (6.35 mmol/l) LDL cholesterol = 110 mg/dl (2.85 mmol/l) HDL cholesterol = 120 mg/dl (3.11 mmol/l) Triglycerides = 75 mg/dl (0.85 mmol/l) Which of the following is the most likely cause of this lipoprotein profile? A. Cholesterol ester transfer protein (CETP) deficiency B. Lecithin cholesterol acyltransferase (LCAT) deficiency C. Hepatic lipase deficiency D. Scavenger receptor B1 (SR B1) deficiency E. ABCA1 deficiency 6 1 8% 7% Question 19 (1/1) Question You are referred a patient with HIV infection who is currently treated with a protease inhibitor and antiviral medications. He has developed mild lipoatrophy and his lipid panel is as follows: Total cholesterol = 280 mg/dl (7.25 mmol/l) LDL cholesterol = 180 mg/dl (4.66 mmol/l) HDL cholesterol = 30 mg/dl (0.78 mmol/l) Triglycerides = 350 mg/dl (3.96 mmol/l) You start treatment with atorvastatin, 10 mg daily, and his LDL cholesterol level decreases to 120 mg/dl (3.11 mmol/l). Which of the following is most likely to occur and prevent the use of a higher statin dosage in this patient? A. Diabetes mellitus B. Myositis C. Inhibition of antiviral agents D. Negative interaction with antibiotics E. Hepatitis 6 28% 8% Question 20 (1/1) Question 20 9

ANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD

ANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed

More information

Hypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC

Hypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and

More information

Pathophysiology of Lipid Disorders

Pathophysiology of Lipid Disorders Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history

More information

Hypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002

Hypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002 Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low

More information

Hyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi

Hyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia

More information

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for

More information

Antihyperlipidemic Drugs

Antihyperlipidemic Drugs Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types

More information

Antihyperlipidemic Drugs

Antihyperlipidemic Drugs Antihyperlipidemic Drugs Lipid disorders: Disorders of lipid metabolism are manifest by elevation of the plasma concentrations of the various lipid and lipoprotein fractions (total and LDL cholesterol,

More information

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,

More information

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien

More information

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,

More information

B. Patient has not reached the percentage reduction goal with statin therapy

B. Patient has not reached the percentage reduction goal with statin therapy Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels

More information

ATP IV: Predicting Guideline Updates

ATP IV: Predicting Guideline Updates Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations

More information

Hi Lipidaholics: This week case is a very common lipid disorder, but what are the medications needed to achieve goals of therapy.

Hi Lipidaholics: This week case is a very common lipid disorder, but what are the medications needed to achieve goals of therapy. LIPID CASE 251 Treating HDL Size Hi Lipidaholics: This week case is a very common lipid disorder, but what are the medications needed to achieve goals of therapy. I was asked about a 44 year old physically

More information

ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS

ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS LABORATORY AND RISK FACTORS OF ATHEROSCLEROSIS S R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty RISK FACTORS FOR CHD Clinical Risk Factors Laboratory Risk Factors MAJOR CLINICAL RISK

More information

Anti Hyperlipidemic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Anti Hyperlipidemic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Anti Hyperlipidemic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Lipoproteins Macromolecular complexes in the blood that transport lipids Apolipoproteins

More information

DYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

DYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism

More information

Approach to Dyslipidemia among diabetic patients

Approach to Dyslipidemia among diabetic patients Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences

More information

DYSLIPIDEMIA RECOMMENDATIONS

DYSLIPIDEMIA RECOMMENDATIONS DYSLIPIDEMIA RECOMMENDATIONS Α. DIAGNOSIS Recommendation 1 INITIAL LIPID PROFILING (Level of evidence II) It is recommended to GPs and other PHC Physicians to assess the lipid profile {total cholesterol

More information

Lipoproteins Metabolism

Lipoproteins Metabolism Lipoproteins Metabolism LEARNING OBJECTIVES By the end of this Lecture, the student should be able to describe: What are Lipoproteins? Describe Lipoprotein Particles. Composition of Lipoproteins. The chemical

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease

Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines 1 This guideline is intended to assist rational and cost-effective prescribing of lipid regulating medications across both primary and

More information

Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk

Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Kim K. Birtcher, PharmD, MS, AACC Clinical Professor University of Houston College of Pharmacy Houston,

More information

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism I. Chylomicrons (exogenous pathway) A. 83% triacylglycerol, 2% protein, 8% cholesterol plus cholesterol esters, 7% phospholipid (esp. phosphatidylcholine)

More information

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown

More information

Lipoprotein Pathophysiology. Lipoprotein Pathophysiology

Lipoprotein Pathophysiology. Lipoprotein Pathophysiology Lipoprotein Pathophysiology Genetic Dyslipidemia Thomas A. Hughes, M.D. Professor of Medicine Division of Endocrinology, Metabolism, and Diabetes University of Tennessee Health Science Center GW is a 47

More information

MOLINA HEALTHCARE OF CALIFORNIA

MOLINA HEALTHCARE OF CALIFORNIA MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel

More information

Lipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology

Lipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring

More information

Chapter (5) Etiology of Low HDL- Cholesterol

Chapter (5) Etiology of Low HDL- Cholesterol Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the

More information

TC =96; HDL-C = 21; Non-HDL-C = 75; LDL-C: less than 10 TG: 357; VLDL-C = 71; TG/HDL-C: 17 TC/HDL-C = 4.5

TC =96; HDL-C = 21; Non-HDL-C = 75; LDL-C: less than 10 TG: 357; VLDL-C = 71; TG/HDL-C: 17 TC/HDL-C = 4.5 LIPID CASE 269 He said - she said?? I want to have some fun with this issue's case discussion. It was sent to me by a respected lipidologist who shared a case first seen by his nurse practitioner. They

More information

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing

More information

Volume 2; Number 11 July 2008

Volume 2; Number 11 July 2008 Volume 2; Number 11 July 2008 CONTENTS Page 1 NICE Clinical Guideline 67: Lipid Modification (May 2008) Page 7 NICE Technology Appraisal 132: Ezetimibe for the treatment of primary (heterozygous familial

More information

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy

More information

Introduction Hyperlipidemia hyperlipoproteinemia Primary hyperlipidemia (Familial) Secondary hyperlipidemia (Acquired)

Introduction Hyperlipidemia hyperlipoproteinemia Primary hyperlipidemia (Familial) Secondary hyperlipidemia (Acquired) Introduction Hyperlipidemia, or hyperlipoproteinemia, is the condition of abnormally elevated levels of any or all lipids and/or lipoproteins in the blood. Hyperlipidemias are divided in primary and secondary

More information

Lipoprotein Particle Profile

Lipoprotein Particle Profile Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular

More information

Fibrate and cardiovascular disease: Evident from meta-analysis. Thongchai Pratipanawatr

Fibrate and cardiovascular disease: Evident from meta-analysis. Thongchai Pratipanawatr Fibrate and cardiovascular disease: Evident from meta-analysis Thongchai Pratipanawatr ??? ย คห นใหม ย คห นกลาง ย คห นเก า ?? Statin era? ย คห นใหม ย คห นกลาง ย คห นเก า CURRENT ROLE OF FIBRATE What are

More information

Zuhier Awan, MD, PhD, FRCPC

Zuhier Awan, MD, PhD, FRCPC Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier

More information

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity

More information

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient

More information

Diabetic Dyslipidemia

Diabetic Dyslipidemia Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals

More information

High density lipoprotein metabolism

High density lipoprotein metabolism High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC

More information

Dyslipidemia. (Med-341)

Dyslipidemia. (Med-341) Dyslipidemia (Med-341) Anwar A Jammah, MD, FRCPC, FACP, CCD, ECNU. Associate Professor of Medicine Consultant Medicine, Endocrinology, Thyroid Oncology Department of Medicine, King Saud University The

More information

Management of Post-transplant hyperlipidemia

Management of Post-transplant hyperlipidemia Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and

More information

Doctor discussion guide:

Doctor discussion guide: Bring this printout to your next doctor s appointment. It will help you and your doctor work together to set goals for treatment, evaluate the success of your treatment, and reduce your risk of side effects.

More information

Classification. Etiology

Classification. Etiology Dyslipidemia Dyslipidemia is the elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high-density lipoprotein level that contributes to the development of atherosclerosis. Causes may

More information

Antihyperlipidemic drugs

Antihyperlipidemic drugs Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual

More information

Pharmacology Challenges: Managing Statin Myalgia

Pharmacology Challenges: Managing Statin Myalgia Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80

More information

( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )

( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD ) 005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,

More information

STRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS. R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty

STRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS. R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty STRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty STRUCTURE OF LIPIDS AND LIPOPROTEINS DEFINTITION: Compounds Insoluble in water But

More information

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:

More information

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:

More information

Chapter VIII: Dr. Sameh Sarray Hlaoui

Chapter VIII: Dr. Sameh Sarray Hlaoui Chapter VIII: Dr. Sameh Sarray Hlaoui Lipoproteins a Lipids are insoluble in plasma. In order to be transported they are combined with specific proteins to form lipoproteins: Clusters of proteins and lipids.

More information

Dyslipidemia. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan

Dyslipidemia. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan Dyslipidemia Objectives: Not given. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan Team Leader: Amal Alshaibi Revised By: Yara Aldigi and Basel almeflh Resources: 435

More information

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,

More information

4/14/2018 DYSLIPIDEMIA CASES. Mary Malloy, MD. I have nothing to disclose

4/14/2018 DYSLIPIDEMIA CASES. Mary Malloy, MD. I have nothing to disclose DYSLIPIDEMIA CASES Mary Malloy, MD I have nothing to disclose 1 Case 1 A 24 year old healthy, slender woman is referred because she has a family history of premature CAD (mother, age 59, had onset of angina

More information

Financial Disclosures

Financial Disclosures 1 Lipids in Type 2 Diabetes July 20, 2013 Abhimanyu Garg, M.D. Professor of Internal Medicine Chief, Division of Nutrition and Metabolic Diseases Distinguished Chair in Human Nutrition Research UT Southwestern

More information

Lipids, lipoproteins and cardiovascular disease

Lipids, lipoproteins and cardiovascular disease Lipids, lipoproteins and cardiovascular disease Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy Cardiovascular disease Plasma enzymes

More information

Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD

Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy

More information

STATIN UTILIZATION MANAGEMENT CRITERIA

STATIN UTILIZATION MANAGEMENT CRITERIA STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,

More information

Learning Objectives. Patient Case

Learning Objectives. Patient Case Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations

More information

Glossary For TheFatNurse s For All Ages Series Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Apolipoprotein

More information

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A ACC/AHA. See American College of Cardiology/ ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors American College of Cardiology/American

More information

MMBS, MMED (Path),MAACB, MACTM, MACRRM

MMBS, MMED (Path),MAACB, MACTM, MACRRM Dr Mere Kende MMBS, MMED (Path),MAACB, MACTM, MACRRM Lecturer- SMSH Brief Overview of Lipids What is dyslipidemia? Classification of hyperlipidemia Primary vs secondary hyperlipidemia Hypercholesterolaemia

More information

The new guidelines issued in PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice

The new guidelines issued in PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice ... PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice Based on a presentation by Daniel J. Rader, MD Presentation Summary The guidelines recently released by the National Cholesterol

More information

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN 1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification

More information

Clinical Approach to Achieving Treatment Targets: Case Vignette Discussion

Clinical Approach to Achieving Treatment Targets: Case Vignette Discussion Clinical Approach to Achieving Treatment Targets: Case Vignette Discussion Om P. Ganda, MD; Kirit Tolia, MD, FACE Postcardiac Follow-up in a 66-Year-Old Man Slide 1. Dr. Ganda: Now we will present a case

More information

Podcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam

Podcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam Podcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam Howard J. Sachs, MD www.12daysinmarch.com Email: Howard@12daysinmarch.com Podcast (Video Recorded

More information

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply

More information

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema

The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,

More information

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global

More information

13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:

13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids: CARDIOVASCULAR DISEASES (CVD) and NUTRITION Major cause of morbidity & mortality in Canada & other developed countries e.g., majority of approved health claims on food labels relate to lowering CVD Relation

More information

2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:

2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug: 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:

More information

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins - Cholesterol: It is a sterol which is found in all eukaryotic cells and contains an oxygen (as a hydroxyl group OH) on Carbon number

More information

Cholesterol metabolism. Function Biosynthesis Transport in the organism Hypercholesterolemia

Cholesterol metabolism. Function Biosynthesis Transport in the organism Hypercholesterolemia Cholesterol metabolism Function Biosynthesis Transport in the organism Hypercholesterolemia - component of all cell membranes - precursor of bile acids steroid hormones vitamin D Cholesterol Sources: dietary

More information

Low HDL-levels: leave it or treat it?

Low HDL-levels: leave it or treat it? Cardiology Update 2011 Davos, 14 02 2011 Low HDL-levels: leave it or treat it? Experts: J.P. Kastelein, Amsterdam and U. Landmesser, Zurich Cases: C. Besler, Zurich and I. Sudano, Zurich Mr H.B., 1960

More information

North Americans consume 100 g of fat per day on

North Americans consume 100 g of fat per day on PRACTICE AT THE BEDSIDE Common problems in the management of hypertriglyceridemia Michelle A. Fung, Jiri J. Frohlich Case A 41-year-old man presents for assessment of severe hypertriglyceridemia. He has

More information

Nature Genetics: doi: /ng.3561

Nature Genetics: doi: /ng.3561 Supplementary Figure 1 Pedigrees of families with APOB p.gln725* mutation and APOB p.gly1829glufs8 mutation (a,b) Pedigrees of families with APOB p.gln725* mutation. (c) Pedigree of family with APOB p.gly1829glufs8

More information

Prof. John Chapman, MD, PhD, DSc

Prof. John Chapman, MD, PhD, DSc Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

Young high risk patients the role of statins Dr. Mohamed Jeilan

Young high risk patients the role of statins Dr. Mohamed Jeilan Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures

More information

Doctor discussion guide:

Doctor discussion guide: Doctor discussion guide: MAnaging Cholesterol Bring this printout to your next doctor s appointment. It will help you and your doctor work together to set goals for treatment, evaluate the success of your

More information

Advances in Lipid Management

Advances in Lipid Management Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center

More information

Cardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk

Cardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

raised triglycerides and residual cardiovascular risk

raised triglycerides and residual cardiovascular risk EARN 3 FREE CPD POINTS cardiovascular Leader in digital CPD for Southern African healthcare professionals Prof Dirk Blom University of Cape Town Heart Centre and Lipid Clinic Groote Schuur Hospital raised

More information

Diabetes Complications Guideline Based Screening, Management, and Referral

Diabetes Complications Guideline Based Screening, Management, and Referral Diabetes Complications Guideline Based Screening, Management, and Referral Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine Assistant Medical Director Altru Diabetes

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

Lipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute

Lipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia

More information

Death is inevitable but premature death is not. Sir Richard Doll

Death is inevitable but premature death is not. Sir Richard Doll Welcome to the Diabetes Care for You webinar Please log onto the conference call so you can hear our presenter From any SCFT Cisco phone dial 800800 From a mobile phone or any other phone dial 01273 242

More information

Primary Prevention Patients aged 85yrs and over

Primary Prevention Patients aged 85yrs and over Rotherham Guideline for the management of Non-Familial Hypercholesterolaemia Type 1 Diabetes Offer lifestyle advice Over 40yrs of age? Diabetic for more than 10 years? Established nephropathy? Other CVD

More information

Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry

Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry Learning Objectives 1. Define lipoproteins and explain the rationale of their formation in blood. 2. List different

More information

Lipid Lowering in Patients at High Risk for Cardiovascular Disease

Lipid Lowering in Patients at High Risk for Cardiovascular Disease Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Lipid/Lipoprotein Structure and Metabolism (Overview)

Lipid/Lipoprotein Structure and Metabolism (Overview) Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures

More information

Dyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Dyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER NORTHWEST AIDS EDUCATION AND TRAINING CENTER Dyslipidemia and HIV Heidi Crane, MD, MPH Madison Metabolic Clinic Associate Professor UW Department of Medicine Presentation prepared by: Heidi Crane, MD,

More information

Hyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE

Hyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No

More information

FORTH VALLEY. LIPID LOWERING GUIDELINE v5 2016

FORTH VALLEY. LIPID LOWERING GUIDELINE v5 2016 FORTH VALLEY LIPID LOWERING GUIDELINE v5 2016 This guideline applies to people over 16 years of age. This guideline is not intended to serve as a standard of medical care or be applicable in every situation.

More information

Fibrates. Spotlight on. Fibric acid derivatives (fibrates) have been used. When should I prescribe fibrates? In this article: Andrew s visit

Fibrates. Spotlight on. Fibric acid derivatives (fibrates) have been used. When should I prescribe fibrates? In this article: Andrew s visit Focus on CME at the University of Alberta Spotlight on By T. K. Lee, MSc (Exp. Medicine), MB, BS, MRCP(UK), ABIM, FRCPC As presented at the Drug Update & Practical Therapeutics Course, November 8, 2002.

More information